Equities researchers at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Spectral AI in a research note issued on Wednesday, April 2nd. HC Wainwright analyst S.

Analysts at HC Wainwright issued their FY2029 EPS estimates for Galectin Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst E. Arce expects that the company will post ...

H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...

H.C. Wainwright lowered the firm’s price target on Galaxy Digital (BRPHF) to C$30 from C$35 and kept a Buy rating on the shares ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

On Monday, H.C. Wainwright reaffirmed its Buy rating and $6.00 price target for Veritone (NASDAQ:VERI), a $116 million market cap company currently trading at $2.61, following the company’s ...